Spanos W J, Peters L J, Oswald M J
Cancer. 1986 Jan 1;57(1):155-9. doi: 10.1002/1097-0142(19860101)57:1<155::aid-cncr2820570131>3.0.co;2-c.
Of 120 patients treated definitively at University of Texas System Cancer Center, M. D. Anderson Hospital for malignant mixed müllerian tumor of the uterus, 67 had their tumors recur. These patients were analyzed for recurrence pattern and response of recurrence to treatment. The most frequent sites of recurrence were the lung and abdomen, accounting for 66% of all first-site recurrences and 80% of all first-site distant metastases. Locoregional recurrences were much less frequent, accounting for 18% of recurrences. There was no apparent change in recurrence pattern with the addition of adjuvant chemotherapy. The effect of adjuvant radiation could not be assessed, because 95% of patients treated surgically received adjunctive radiation. The survival after treatment of recurrence was shortest for patients with bone, brain, or liver metastases (median, 4 months). There were four long-term survivors (more than 36 months). Patients with resectable recurrences had the highest response rates. Response to chemotherapy alone was uniformly poor (6% response rate).
在得克萨斯大学系统癌症中心MD安德森医院接受子宫恶性混合苗勒管肿瘤根治性治疗的120例患者中，67例肿瘤复发。对这些患者的复发模式以及复发对治疗的反应进行了分析。最常见的复发部位是肺和腹部，占所有首发部位复发的66%，占所有首发远处转移的80%。局部区域复发则少见得多，占复发的18%。辅助化疗的加入并未使复发模式发生明显改变。由于95%接受手术治疗的患者接受了辅助放疗，因此无法评估辅助放疗的效果。骨、脑或肝转移患者复发治疗后的生存期最短（中位生存期为4个月）。有4例长期存活者（超过36个月）。可切除复发患者的缓解率最高。单纯化疗的反应普遍较差（缓解率为6%）。
